PriceTargets.com logo

Bio-Techne - TECH Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $107.86
  • Forecasted Upside: 32.85%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$81.19 As of 01/27/2023 01:00 AM ET
▲ +0.87 (1.08%)

This chart shows the closing price for TECH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Bio-Techne Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TECH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TECH

Analyst Price Target is $107.86
▲ +32.85% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Bio-Techne in the last 3 months. The average price target is $107.86, with a high forecast of $125.00 and a low forecast of $89.00. The average price target represents a 32.85% upside from the last price of $81.19.

This chart shows the closing price for TECH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 polled investment analysts is to buy stock in Bio-Techne. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/7/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/4/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/2/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2023

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/10/2023Wells Fargo & CompanyUpgradeUnderweight ➝ Equal Weight$90.00Low
12/13/2022Deutsche Bank AktiengesellschaftInitiated CoverageBuy$100.00Low
12/12/2022CitigroupUpgradeNeutral ➝ Buy$81.25 ➝ $100.00Low
12/6/2022Royal Bank of CanadaInitiated CoverageSector Perform$89.00Low
12/5/2022StephensLower TargetOverweight ➝ Overweight$105.00Low
11/2/2022Craig HallumLower Target$125.25 ➝ $104.75Low
11/2/2022BenchmarkLower Target$135.00 ➝ $120.00Low
11/2/2022Robert W. BairdLower Target$117.50 ➝ $111.50N/A
11/2/2022SVB LeerinkLower TargetOutperform$137.50 ➝ $125.00Low
8/24/2022Credit Suisse GroupInitiated CoverageOutperform$116.25Low
8/16/2022Wells Fargo & CompanyLower TargetUnderweight$92.50 ➝ $90.00Low
8/5/2022Robert W. BairdLower Target$125.00 ➝ $117.50Low
8/5/2022StephensLower TargetOverweight$125.00 ➝ $120.00Low
5/5/2022Robert W. BairdLower Target$130.00 ➝ $125.00High
5/5/2022KeyCorpLower Target$150.00 ➝ $125.00High
4/25/2022Wells Fargo & CompanyDowngradeEqual Weight ➝ Underweight$100.00 ➝ $92.50Medium
2/2/2022SVB LeerinkBoost TargetOutperform$132.50 ➝ $143.75High
11/3/2021Robert W. BairdBoost TargetOutperform$130.50 ➝ $137.00High
8/24/2021ArgusBoost TargetBuy$122.50 ➝ $135.00High
8/6/2021Robert W. BairdBoost TargetOutperform$107.50 ➝ $130.50High
8/5/2021BenchmarkBoost TargetBuy$120.00 ➝ $135.00High
6/29/2021SVB LeerinkBoost TargetOutperform$112.50 ➝ $120.00Low
6/18/2021ArgusBoost TargetBuy$110.00 ➝ $122.50High
5/7/2021Robert W. BairdBoost TargetOutperform$102.50 ➝ $107.50Medium
3/8/2021StephensUpgradeEqual Weight ➝ Overweight$95.00 ➝ $106.25High
2/23/2021Stifel NicolausUpgradeHold ➝ Buy$108.75Low
2/3/2021CitigroupBoost TargetNeutral$77.50 ➝ $100.00Low
2/3/2021Craig HallumBoost TargetBuy$88.00 ➝ $110.00Medium
1/25/2021BenchmarkBoost TargetBuy$80.00 ➝ $102.50Low
11/9/2020KeyCorpInitiated CoverageSector Weight ➝ Sector Weight$85.00Low
11/6/2020Robert W. BairdBoost TargetOutperform$72.25 ➝ $80.00Low
11/6/2020SVB LeerinkBoost TargetOutperform$71.25 ➝ $80.00Low
9/30/2020Atlantic SecuritiesInitiated CoverageOverweight$91.25Low
8/5/2020SVB LeerinkBoost TargetOutperform$66.25 ➝ $71.25Medium
8/4/2020Wells Fargo & CompanyReiterated RatingHoldMedium
8/4/2020Craig HallumUpgradeHold ➝ Buy$52.75 ➝ $82.00Medium
7/15/2020StephensDowngradeOverweight ➝ Equal Weight$63.25 ➝ $68.25High
6/18/2020CitigroupBoost TargetNeutral$57.50 ➝ $65.00Low
5/27/2020Stifel NicolausDowngradeBuy ➝ Hold$61.25 ➝ $65.00Medium
5/14/2020BenchmarkInitiated CoverageBuy$72.50Low
5/1/2020StephensBoost TargetOverweight$57.50 ➝ $63.25High
5/1/2020Wells Fargo & CompanyBoost TargetEqual Weight$47.50 ➝ $55.00High
5/1/2020Stifel NicolausBoost TargetBuy$52.50 ➝ $61.25Medium
4/20/2020CitigroupBoost TargetNeutral$43.75 ➝ $53.75Low
4/20/2020Craig HallumLower TargetBuy$54.50 ➝ $52.75Medium
4/2/2020Stifel NicolausLower TargetBuy$58.75 ➝ $52.50Medium
3/30/2020Wells Fargo & CompanyLower TargetEqual Weight$56.25 ➝ $47.50High
3/20/2020CitigroupLower TargetNeutral$56.25 ➝ $43.75High
2/24/2020Eight CapitalDowngradeBuy ➝ NeutralLow
2/5/2020Robert W. BairdBoost TargetOutperform$55.50 ➝ $57.50Low
2/5/2020CitigroupLower TargetNeutral$58.75 ➝ $56.25Low
1/8/2020StephensInitiated CoverageOverweightLow
1/7/2020Wells Fargo & CompanyInitiated CoverageEqual Weight$57.50Low
1/6/2020CitigroupInitiated CoverageNeutral$58.75Low
11/14/2019Stifel NicolausInitiated CoverageBuy$58.75High
9/26/2019SVB LeerinkReiterated RatingOutperform$57.50 ➝ $60.00Low
7/2/2019Janney Montgomery ScottUpgradeNeutral ➝ Buy$50.00 ➝ $67.50High
3/4/2019ArgusReiterated RatingBuyMedium
2/5/2019Craig HallumReiterated RatingHold$38.50 ➝ $44.75Low
1/14/2019StephensUpgradeEqual Weight ➝ Overweight$45.00Low
11/30/2018The Goldman Sachs GroupSet TargetHold$41.25Low
10/31/2018Craig HallumDowngradeBuy ➝ Hold$53.75 ➝ $38.50Medium
10/17/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$47.50Medium
10/2/2018ArgusBoost TargetBuy ➝ Buy$52.50 ➝ $57.50Low
8/9/2018CitigroupBoost TargetBuy ➝ Buy$40.00 ➝ $51.25Low
8/8/2018Craig HallumBoost TargetBuy$40.00 ➝ $53.75Medium
8/8/2018Robert W. BairdBoost TargetOutperform ➝ Positive$40.50 ➝ $47.75Medium
8/8/2018SVB LeerinkSet TargetOutperform$40.00 ➝ $47.50Medium
6/27/2018Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$41.25High
6/15/2018ArgusInitiated CoverageBuy$46.25Medium
5/3/2018Deutsche Bank AktiengesellschaftLower TargetBuy ➝ Buy$41.75 ➝ $41.25High
5/3/2018SVB LeerinkSet TargetBuy$37.75 ➝ $40.00Low
3/1/2018Deutsche Bank AktiengesellschaftSet TargetBuy ➝ Buy$38.50 ➝ $40.75Low
2/7/2018Craig HallumReiterated RatingBuy$35.00 ➝ $40.00Medium
2/7/2018Robert W. BairdBoost TargetOutperform ➝ Outperform$38.50 ➝ $39.25Medium
(Data available from 1/29/2018 forward)

News Sentiment Rating

0.41 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2022
  • 5 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/2/2022
  • 9 very positive mentions
  • 18 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2022
  • 8 very positive mentions
  • 23 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2022
  • 5 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2022
  • 5 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2022
  • 5 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
12/30/2022
  • 3 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2023

Current Sentiment

  • 3 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Bio-Techne logo
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics & Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. T
Read More

Today's Range

Now: $81.19
Low: $79.32
High: $82.01

50 Day Range

MA: $87.62
Low: $79.83
High: $327.07

52 Week Range

Now: $81.19
Low: $68.00
High: $113.81

Volume

864,960 shs

Average Volume

895,702 shs

Market Capitalization

$12.74 billion

P/E Ratio

45.48

Dividend Yield

0.39%

Beta

1.25

Frequently Asked Questions

What sell-side analysts currently cover shares of Bio-Techne?

The following Wall Street analysts have issued stock ratings on Bio-Techne in the last year: Benchmark Co., Citigroup Inc., Craig Hallum, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, KeyCorp, Robert W. Baird, Royal Bank of Canada, Stephens, StockNews.com, SVB Leerink LLC, and Wells Fargo & Company.
View the latest analyst ratings for TECH.

What is the current price target for Bio-Techne?

11 Wall Street analysts have set twelve-month price targets for Bio-Techne in the last year. Their average twelve-month price target is $107.86, suggesting a possible upside of 32.9%. KeyCorp has the highest price target set, predicting TECH will reach $125.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $89.00 for Bio-Techne in the next year.
View the latest price targets for TECH.

What is the current consensus analyst rating for Bio-Techne?

Bio-Techne currently has 2 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TECH will outperform the market and that investors should add to their positions of Bio-Techne.
View the latest ratings for TECH.

What other companies compete with Bio-Techne?

Other companies that are similar to Bio-Techne include Qiagen, Neurocrine Biosciences, Repligen, Halozyme Therapeutics and Exelixis. Learn More about companies similar to Bio-Techne.

How do I contact Bio-Techne's investor relations team?

Bio-Techne's physical mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company's listed phone number is (612) 379-8854 and its investor relations email address is [email protected] The official website for Bio-Techne is www.bio-techne.com. Learn More about contacing Bio-Techne investor relations.